A new study published in The BMJ shows that people who discontinue prescription weight loss medications often regain the weight they lost and lose many of the health improvements achieved during treatment. Benefits linked to heart and metabolic health, such as improved cholesterol levels and blood pressure, tend to diminish once medication use stops.
Researchers found that, on average, individuals regained approximately 0.4 kilograms (0.88 pounds) per month after stopping treatment. Based on this trend, body weight and key markers for diabetes and heart disease were projected to return to pre-treatment levels in under two years.
The pace of weight regain after stopping medications was notably faster than weight regained after lifestyle-based interventions like diet and exercise, occurring nearly four times more quickly regardless of initial weight loss. “This evidence suggests that despite their success in achieving initial weight loss, these drugs alone may not be sufficient for long-term weight control,” the researchers wrote.
GLP-1 Medications Transform Obesity Treatment, But Many Discontinue Early
Recent prescription options, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound), have revolutionized obesity treatment by enabling significant weight loss for many patients.
Despite their effectiveness, about half of patients discontinue GLP-1 drugs within a year. This high rate of discontinuation underscores the importance of understanding the long-term effects on weight and cardiometabolic health after stopping medication.
How the Study Tracked Weight Regain
Researchers from the University of Oxford analyzed 37 clinical trials and observational studies, published through February 2025, involving a total of 9,341 adults who used FDA-approved weight loss medications. Treatment duration averaged 39 weeks, with follow-up periods lasting around 32 weeks after discontinuation. Outcomes were compared with non-drug approaches, including behavioral weight management programs and placebo treatments.
The team assessed study quality and potential bias using established tools to maintain consistency across the analysis.
Weight and Health Benefits Fade Within Years
Across all studies, participants regained weight at an average rate of 0.4 kilograms per month after stopping medication, projecting a return to pre-treatment weight within roughly 1.7 years. Cardiometabolic markers followed a similar pattern, with key indicators for heart disease and diabetes estimated to revert to baseline within about 1.4 years.
Weight regain after drug-based interventions was consistently faster than after behavioral programs, with an average difference of 0.3 kilograms per month, independent of the amount of weight initially lost.
Limitations and Strengths of the Research
The study’s authors note several limitations, including that only eight studies included newer GLP-1 medications and none tracked patients for more than 12 months after cessation. Additionally, relatively few studies were rated as low risk for bias.
Nonetheless, the researchers used three analytical methods, all producing similar results, which strengthens confidence in the overall findings.
Experts Stress Long-Term Approaches Beyond Medication
The study underscores that short-term medication use is unlikely to provide lasting weight control. Authors recommend further research into cost-effective, long-term strategies and emphasize the importance of primary prevention.
A U.S. researcher writing in a linked editorial noted, “The study findings cast doubt on the notion that GLP-1 receptor agonists are a perfect cure for obesity. People taking these medications should be aware of the high discontinuation rate and potential consequences of stopping treatment.”
Experts agree that healthy dietary and lifestyle practices should remain the foundation of obesity management. Medications like GLP-1 receptor agonists are best used as adjuncts, supporting long-term habits that help prevent weight gain while providing broader health benefits.
